West Pharmaceutical Services reported an 8.7% increase in Q3 2026 net sales to $874.5 million and a 35.7% rise in adjusted diluted EPS to $2.66. The company saw strong organic growth, particularly in its High-Value Product Components segment, driving margin expansion and profitability. As a result, West raised its full-year 2026 net sales guidance to $3.41-$3.42 billion and adjusted EPS guidance to $9.38-$9.48. The company also increased its quarterly dividend by 18%, signaling confidence in ongoing performance.
West Pharmaceutical Services reported its Q3 2026 results. For readers following the Health sector, here is Pluang's market snapshot as of Oct 29, 2026 16:11 WIB: 86 of 150 priced Health-sector US stocks rose today. Notable movers include TDOC at USD 7.46 with an 8.43% increase and a typical hold time of 39 days, CLPT at USD 11.00 up 4.17% with balanced buy/sell activity, and BAX at USD 26.33 rising 3.42% with a typical hold time of 72 days.
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...
Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...
Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...
